ADVANZ PHARMA (CXRXF) 6-K Current report (foreign)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of: May 2018

Commission File Number: 001- 37413

Concordia International Corp.

(Translation of registrant’s name into English)

277 Lakeshore Road East, Suite 302

Oakville, Ontario

L6J 1H9

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F xForm 40-Fo

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

On May 29, 2018, Concordia International Corp. (“Concordia”) filed a certificate of abridgement on the System for Electronic Document Analysis and Retrieval (SEDAR). In conjunction with this filing Concordia is filing the following exhibit:

Exhibit 99.1        Certificate of Abridgement, dated May 29, 2018

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Concordia International Corp.
By:	/s/ David Price
	Name:	David Price
	Title:	Chief Financial Officer

Date: May 29, 2018

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 99.1	Certificate of Abridgement, dated May 29, 2018